aminolevulinic acid has been researched along with Erythema in 47 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aminolevulinic acid (ALA) photodynamic therapy (PDT) is an established treatment option for actinic keratosis (AK), and recently fractional carbon dioxide (CO2) laser was shown to improve outcomes; but studies of short incubation photosensitizer are lacking." | 9.24 | Randomized, Controlled Trial of Fractional Carbon Dioxide Laser Resurfacing Followed by Ultrashort Incubation Aminolevulinic Acid Blue Light Photodynamic Therapy for Actinic Keratosis. ( Alexiades, M, 2017) |
| "Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment." | 9.20 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| "To determine the impact of skin pretreatment with microneedles (MNs) on ALA- and MAL-induced protoporphyrin IX (PpIX) production, as well as MN impact on pain sensations during light exposure and erythema after PDT." | 9.14 | Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. ( Donnelly, RF; Garland, MJ; Iani, V; Juzeniene, A; Mikolajewska, P; Moan, J; Morrow, DI; Singh, TR, 2010) |
| " Here, the ability of discrete PS fluorescence-based metrics (absolute and percent PS photobleaching and PS re-accumulation post-PDT) to predict the clinical phototoxic response (erythema) resulting from 5-aminolevulinic acid PDT was compared with discrete SOL (DSOL)-based metrics (DSOL counts pre-PDT and change in DSOL counts pre/post-PDT) in healthy human skin." | 7.80 | Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema. ( Anbil, S; Davis, SJ; Elrington, S; Hasan, T; Kositratna, G; Lee, S; Mallidi, S; Manstein, D; Pogue, B; Schoenfeld, D, 2014) |
| "However, pain was not an exclusive indicator of PpIX concentration as many patients with low PpIX concentration reported high pain." | 6.80 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| "Conventional 5-aminolevulinic acid-photodynamic (ALA-PDT) therapy (10-20%) has been widely applied for moderate-to-severe acne." | 5.69 | The quantitative analysis of low-concentration (2%) ALA-PDT assisted with Q-switch 1064-nm Nd:YAG laser for acne vulgaris treatment. ( Chang, CC; Chen, YT; Chiang, HM; Huang, YH; Lin, BS; Lin, YJ; Liu, PH; Lu, ME; Shen, JW, 2023) |
| "Aminolevulinic acid (ALA) photodynamic therapy (PDT) is an established treatment option for actinic keratosis (AK), and recently fractional carbon dioxide (CO2) laser was shown to improve outcomes; but studies of short incubation photosensitizer are lacking." | 5.24 | Randomized, Controlled Trial of Fractional Carbon Dioxide Laser Resurfacing Followed by Ultrashort Incubation Aminolevulinic Acid Blue Light Photodynamic Therapy for Actinic Keratosis. ( Alexiades, M, 2017) |
| "Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment." | 5.20 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| " Objective and visual erythema, protoporphyrin IX (PpIX) fluorescence and pain were evaluated." | 5.19 | Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial. ( Petersen, B; Wiegell, SR; Wulf, HC, 2014) |
| "To determine the impact of skin pretreatment with microneedles (MNs) on ALA- and MAL-induced protoporphyrin IX (PpIX) production, as well as MN impact on pain sensations during light exposure and erythema after PDT." | 5.14 | Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. ( Donnelly, RF; Garland, MJ; Iani, V; Juzeniene, A; Mikolajewska, P; Moan, J; Morrow, DI; Singh, TR, 2010) |
| "To evaluate the efficacy and safety of LPDL alone versus LPDL in photodynamic therapy with methylaminolevulinic acid (MAL-LPDL) for acne vulgaris." | 5.13 | Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial. ( Haedersdal, M; Togsverd-Bo, K; Wiegell, SR; Wulf, HC, 2008) |
| "Topical 5-aminolevulinic acid (ALA) and various light sources have been used to treat actinic keratoses and acne." | 5.12 | Efficacy of microdermabrasion preceding ALA application in reducing the incubation time of ALA in laser PDT. ( Frew, KE; George, D; Katz, BE; Maiwald, DC; Truong, S, 2007) |
| " Here, the ability of discrete PS fluorescence-based metrics (absolute and percent PS photobleaching and PS re-accumulation post-PDT) to predict the clinical phototoxic response (erythema) resulting from 5-aminolevulinic acid PDT was compared with discrete SOL (DSOL)-based metrics (DSOL counts pre-PDT and change in DSOL counts pre/post-PDT) in healthy human skin." | 3.80 | Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema. ( Anbil, S; Davis, SJ; Elrington, S; Hasan, T; Kositratna, G; Lee, S; Mallidi, S; Manstein, D; Pogue, B; Schoenfeld, D, 2014) |
| "The efficacy of photodynamic therapy (PDT) using topical 5-aminolevulinic acid (ALA) for the treatment of actinic keratosis (AKs) is lower on the distal extremities compared with the head and neck areas." | 3.80 | Temperature-modulated photodynamic therapy for the treatment of actinic keratosis on the extremities: a pilot study. ( Anderson, RR; Sakamoto, FH; Willey, A, 2014) |
| "Acute skin inflammation occurs following topical aminolevulinic acid-photodynamic therapy (ALA-PDT), but its nature and mediation are ill defined." | 3.73 | Histamine is released following aminolevulinic acid-photodynamic therapy of human skin and mediates an aminolevulinic acid dose-related immediate inflammatory response. ( Brooke, RC; Church, MK; Clough, GF; Friedmann, PS; Rhodes, LE; Sidhu, MK; Sinha, A; Watson, RE, 2006) |
| " The objective of this study was to evaluate the impact of antihistamines upon adverse effects following ALA-PDT." | 2.84 | A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy. ( Goldman, MP; Jones, IT; Vanaman Wilson, MJ; Wu, DC, 2017) |
| "Aminolevulinic acid or VEH was applied to face or scalp as a broad area application for 1, 2, or 3 hours or as a spot application for 2 hours before blue light activation." | 2.82 | Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp. ( Berg, JE; Ferdon, MB; Houlihan, A; Pariser, DM, 2016) |
| "However, pain was not an exclusive indicator of PpIX concentration as many patients with low PpIX concentration reported high pain." | 2.80 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| "The main side-effects of PDT are post-treatment erythema and oedema, and pain during illumination." | 2.79 | Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial. ( Petersen, B; Wiegell, SR; Wulf, HC, 2014) |
| "Pain was measured using a visual analog scale immediately and 8 h after PDT." | 2.78 | Dermatology life quality index and side effects after topical photodynamic therapy of actinic keratosis. ( Enk, AH; Gholam, P; Kroehl, V, 2013) |
| "Pain is a major side effect thereof, and it affects the treatment compliance and acceptance." | 2.78 | Correlations between photoactivable porphyrins' fluorescence, erythema and the pain induced by PDT on normal skin using ALA-derivatives. ( Barge, J; Glanzmann, T; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2013) |
| "Erythema was significantly more severe (P=0." | 2.76 | Effect of retinoid pretreatment on outcomes of patients treated by photodynamic therapy for actinic keratosis of the hand and forearm. ( Galitzer, BI, 2011) |
| "Hyperpigmentation was more likely to occur in skin appendage disorders (P<0." | 1.72 | Adverse reactions of ALA-PDT for the treatment of cutaneous diseases: A retrospective study. ( Shi, L; Wang, P; Wang, X; Yan, G; Yang, J; Zhang, G; Zhang, H; Zhang, L; Zhang, Y; Zhou, Z, 2022) |
| "Erythema was assessed by naked eye and laser Doppler perfusion imaging (LDPI), at baseline and at 1, 5, 24 and 48 h following illumination." | 1.37 | Increased cutaneous oxygen availability by topical application of hydrogen peroxide cream enhances the photodynamic reaction to topical 5-aminolevulinic acid-methyl ester. ( Anderson, CD; Manifold, RN, 2011) |
| " In 13 healthy volunteers, we assessed the time course and dose-response of the acute cutaneous response(s) to ALA-PDT, the impact of H(1) antihistamine blockade, and measured dermal histamine release." | 1.33 | Histamine is released following aminolevulinic acid-photodynamic therapy of human skin and mediates an aminolevulinic acid dose-related immediate inflammatory response. ( Brooke, RC; Church, MK; Clough, GF; Friedmann, PS; Rhodes, LE; Sidhu, MK; Sinha, A; Watson, RE, 2006) |
| "Photodynamic therapy (PDT) with topical 5-aminolevulinic acid (ALA) is increasingly employed for skin cancer, yet ALA dosing is crude." | 1.30 | Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. ( Anderson, RR; Kollias, N; Rhodes, LE; Tsoukas, MM, 1997) |
| "Resultant erythema was measured by reflectance spectroscopy." | 1.30 | Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. ( Anderson, RR; Kollias, N; Rhodes, LE; Tsoukas, MM, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.38) | 18.2507 |
| 2000's | 13 (27.66) | 29.6817 |
| 2010's | 28 (59.57) | 24.3611 |
| 2020's | 3 (6.38) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, L | 1 |
| Yang, J | 2 |
| Zhang, L | 1 |
| Zhang, Y | 1 |
| Yan, G | 1 |
| Zhang, H | 1 |
| Wang, P | 1 |
| Zhang, G | 1 |
| Zhou, Z | 1 |
| Wang, X | 2 |
| Chen, YT | 1 |
| Lin, YJ | 1 |
| Chang, CC | 1 |
| Liu, PH | 1 |
| Huang, YH | 1 |
| Shen, JW | 1 |
| Lu, ME | 1 |
| Chiang, HM | 1 |
| Lin, BS | 1 |
| Alexiades, M | 1 |
| Vanaman Wilson, MJ | 1 |
| Jones, IT | 1 |
| Wu, DC | 1 |
| Goldman, MP | 2 |
| Bay, C | 1 |
| Vissing, AC | 1 |
| Thaysen-Petersen, D | 1 |
| Lerche, CM | 3 |
| Togsverd-Bo, K | 2 |
| Heydenreich, J | 1 |
| Haedersdal, M | 2 |
| Serra-Guillén, C | 1 |
| Nagore, E | 1 |
| Bancalari, E | 1 |
| Kindem, S | 1 |
| Sanmartín, O | 1 |
| Llombart, B | 1 |
| Requena, C | 1 |
| Serra-Guillén, I | 1 |
| Calomarde, L | 1 |
| Diago, A | 1 |
| Bernia, E | 1 |
| Guillén, C | 1 |
| Wiegell, SR | 6 |
| Johansen, UB | 1 |
| Wulf, HC | 8 |
| Fusano, M | 1 |
| Zane, C | 1 |
| Calzavara-Pinton, P | 1 |
| Bencini, PL | 1 |
| Gholam, P | 1 |
| Kroehl, V | 1 |
| Enk, AH | 1 |
| Brooke, RC | 3 |
| Sidhu, M | 1 |
| Sinha, A | 2 |
| Watson, RE | 2 |
| Friedmann, PS | 2 |
| Clough, GF | 2 |
| Rhodes, LE | 5 |
| Ibbotson, SH | 2 |
| Barge, J | 1 |
| Glanzmann, T | 1 |
| Zellweger, M | 1 |
| Salomon, D | 1 |
| van den Bergh, H | 1 |
| Wagnières, G | 1 |
| Mallidi, S | 1 |
| Anbil, S | 1 |
| Lee, S | 1 |
| Manstein, D | 1 |
| Elrington, S | 1 |
| Kositratna, G | 1 |
| Schoenfeld, D | 1 |
| Pogue, B | 1 |
| Davis, SJ | 1 |
| Hasan, T | 2 |
| Petersen, B | 3 |
| Shin, HT | 1 |
| Kim, JH | 1 |
| Shim, J | 1 |
| Lee, JH | 2 |
| Lee, DY | 1 |
| Yang, JM | 1 |
| Willey, A | 1 |
| Anderson, RR | 2 |
| Sakamoto, FH | 1 |
| Fabricius, S | 2 |
| Philipsen, PA | 2 |
| Neittaanmäki-Perttu, N | 1 |
| Neittaanmäki, E | 1 |
| Pölönen, I | 1 |
| Snellman, E | 1 |
| Grönroos, M | 1 |
| Kanick, SC | 1 |
| Davis, SC | 1 |
| Zhao, Y | 1 |
| Sheehan, KL | 1 |
| Maytin, EV | 1 |
| Pogue, BW | 1 |
| Chapman, MS | 1 |
| Pariser, DM | 1 |
| Houlihan, A | 1 |
| Ferdon, MB | 1 |
| Berg, JE | 1 |
| Nissen, CV | 1 |
| Heerfordt, IM | 1 |
| Mikkelsen, CS | 1 |
| Mikolajewska, P | 2 |
| Iani, V | 2 |
| Juzeniene, A | 2 |
| Moan, J | 2 |
| Donnelly, RF | 1 |
| Garland, MJ | 1 |
| Morrow, DI | 1 |
| Singh, TR | 1 |
| Wang, H | 1 |
| Huang, Z | 1 |
| Palm, MD | 1 |
| Manifold, RN | 1 |
| Anderson, CD | 1 |
| Zhang, LW | 1 |
| Al-Suwayeh, SA | 1 |
| Hung, CF | 1 |
| Chen, CC | 1 |
| Fang, JY | 1 |
| Galitzer, BI | 1 |
| Bissonnette, R | 1 |
| Tremblay, JF | 1 |
| Juzenas, P | 1 |
| Boushira, M | 1 |
| Lui, H | 1 |
| Choudry, K | 1 |
| Farrar, W | 1 |
| Clark, C | 1 |
| Dawe, RS | 1 |
| Moseley, H | 1 |
| Ferguson, J | 1 |
| Dover, JS | 1 |
| Bhatia, AC | 1 |
| Stewart, B | 1 |
| Arndt, KA | 1 |
| Katz, B | 1 |
| Patel, V | 1 |
| Misra, A | 1 |
| Maybury, K | 1 |
| Eltigani, TA | 1 |
| Sidhu, MK | 1 |
| Church, MK | 1 |
| Katz, BE | 1 |
| Truong, S | 1 |
| Maiwald, DC | 1 |
| Frew, KE | 1 |
| George, D | 1 |
| Ruiz-Rodriguez, R | 1 |
| López, L | 1 |
| Candelas, D | 1 |
| Zelickson, B | 1 |
| Yung, A | 1 |
| Stables, GI | 1 |
| Fernandez, C | 1 |
| Williams, J | 1 |
| Bojar, RA | 1 |
| Goulden, V | 1 |
| Tsoukas, MM | 1 |
| Kollias, N | 1 |
| Tosca, AD | 1 |
| Balas, CJ | 1 |
| Stefanidou, MP | 1 |
| Katsantonis, JC | 1 |
| Georgiou, SK | 1 |
| Tzardi, MN | 1 |
| Fink-Puches, R | 1 |
| Hofer, A | 1 |
| Smolle, J | 1 |
| Kerl, H | 1 |
| Wolf, P | 1 |
| Gerscher, S | 1 |
| Connelly, JP | 1 |
| Beijersbergen Van Henegouwen, GM | 1 |
| MacRobert, AJ | 1 |
| Watt, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy[NCT02451579] | 20 participants (Anticipated) | Interventional | 2015-02-28 | Completed | |||
| Indoor Daylight Photo Dynamic Therapy (PDT) for Actinic Keratosis[NCT03805737] | 43 participants (Actual) | Interventional | 2019-11-01 | Completed | |||
| Portable Measurement of Protoporphyrin IX in the Skin[NCT04223570] | 218 participants (Anticipated) | Observational | 2022-12-01 | Enrolling by invitation | |||
| Evaluation of the Formulation of 5-aminolevulinic Acid With Dimethylsulfoxide in Photodynamic Therapy for Treatment of Actinic Keratosis[NCT01459393] | Phase 3 | 137 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for aminolevulinic acid and Erythema
| Article | Year |
|---|---|
Ameluz for actinic keratoses.
Topics: Administration, Topical; Aminolevulinic Acid; Drug Compounding; Erythema; Gels; Humans; Keratosis, A | 2016 |
28 trials available for aminolevulinic acid and Erythema
| Article | Year |
|---|---|
The quantitative analysis of low-concentration (2%) ALA-PDT assisted with Q-switch 1064-nm Nd:YAG laser for acne vulgaris treatment.
Topics: Acne Vulgaris; Aminolevulinic Acid; Erythema; Humans; Lasers, Solid-State; Melanins; Photochemothera | 2023 |
Randomized, Controlled Trial of Fractional Carbon Dioxide Laser Resurfacing Followed by Ultrashort Incubation Aminolevulinic Acid Blue Light Photodynamic Therapy for Actinic Keratosis.
Topics: Aminolevulinic Acid; Erythema; Esthetics; Follow-Up Studies; Humans; Hyperpigmentation; Keratosis, A | 2017 |
A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Cetirizine; Double-Blind Method; Drug Eruption | 2017 |
Skin reactions after photodynamic therapy are unaffected by 839 nm photobiomodulation therapy: A randomized, double-blind, placebo-controlled, clinical trial.
Topics: Adolescent; Adult; Aminolevulinic Acid; Double-Blind Method; Edema; Erythema; Female; Humans; Low-Le | 2017 |
A randomized intraindividual comparative study of methyl-5-aminolaevulinate vs. 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) in photodynamic therapy for actinic keratosis of the face and scalp.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Erythema; Face; Female; Humans; Keratosis, Act | 2018 |
Pulse-Daylight-Photodynamic Therapy in Combination with Corticosteroid and Brimonidine Tartrate for Multiple Actinic Keratoses: A Randomized Clinical Trial.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adrenergic alpha-2 Receptor Agonists; Aminolevul | 2019 |
Dermatology life quality index and side effects after topical photodynamic therapy of actinic keratosis.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Edema; Erythema; Facial Dermatoses; Female; Humans; Ke | 2013 |
Prostaglandin E2 and nitric oxide mediate the acute inflammatory (erythemal) response to topical 5-aminolaevulinic acid photodynamic therapy in human skin.
Topics: Administration, Cutaneous; Adult; Aged; Aminolevulinic Acid; Cyclooxygenase Inhibitors; Dinoprostone | 2013 |
Correlations between photoactivable porphyrins' fluorescence, erythema and the pain induced by PDT on normal skin using ALA-derivatives.
Topics: Adult; Aminolevulinic Acid; Dose-Response Relationship, Radiation; Erythema; Fluorescence; Humans; M | 2013 |
Light protection of the skin after photodynamic therapy reduces inflammation: an unblinded randomized controlled study.
Topics: Aminolevulinic Acid; Drug Eruptions; Erythema; Female; Fluorescence; Humans; Keratosis, Actinic; Mal | 2014 |
Photodynamic therapy using a new formulation of 5-aminolevulinic acid for wrinkles in Asian skin: A randomized controlled split face study.
Topics: Adult; Aminolevulinic Acid; Asian People; Erythema; Face; Female; Humans; Intense Pulsed Light Thera | 2015 |
Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents; C | 2014 |
Safety of Novel Amino-5-laevulinate Photosensitizer Precursors in Photodynamic Therapy for Healthy Human Skin.
Topics: Administration, Cutaneous; Adult; Aminolevulinic Acid; Double-Blind Method; Erythema; Healthy Volunt | 2016 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pulse photodynamic therapy reduces inflammation without compromising efficacy in the treatment of multiple mild actinic keratoses of the face and scalp: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Erythema; Facial Dermatoses; Female; Fluorescence; Hum | 2016 |
Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Erythema; Facial Dermatoses; Female; Humans; Ke | 2016 |
Increased protoporphyrin IX accumulation does not improve the effect of photodynamic therapy for actinic keratosis: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Curettage; Drug Eruptions; Erythema; Female; Fluoresce | 2017 |
Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema.
Topics: Administration, Cutaneous; Adult; Aminolevulinic Acid; Erythema; Female; Humans; Light; Male; Needle | 2010 |
Safety and efficacy comparison of blue versus red light sources for photodynamic therapy using methyl aminolevulinate in photodamaged skin.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cohort Studies; Erythema; Female; Humans; Light | 2011 |
Effect of retinoid pretreatment on outcomes of patients treated by photodynamic therapy for actinic keratosis of the hand and forearm.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Dermatologic Agents; Erythe | 2011 |
The relation between methyl aminolevulinate concentration and inflammation after photodynamic therapy in healthy volunteers.
Topics: Adult; Aminolevulinic Acid; Dose-Response Relationship, Drug; Erythema; Humans; Male; Middle Aged; P | 2013 |
Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques.
Topics: Administration, Oral; Aminolevulinic Acid; Apoptosis; CD3 Complex; Epidermis; Erythema; Humans; Phot | 2002 |
The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Car | 2003 |
Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging.
Topics: Aged; Aminolevulinic Acid; Edema; Erythema; Esthetics; Humans; Middle Aged; Patient Satisfaction; Ph | 2005 |
Efficacy of microdermabrasion preceding ALA application in reducing the incubation time of ALA in laser PDT.
Topics: Acne Vulgaris; Administration, Topical; Adult; Aminolevulinic Acid; Erythema; Humans; Keratosis; Las | 2007 |
Enhanced efficacy of photodynamic therapy after fractional resurfacing: fractional photodynamic rejuvenation.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Cosmetic Techniques; Edema; Erythema; Female; Follow | 2007 |
Microbiological effect of photodynamic therapy (PDT) in healthy volunteers: a comparative study using methyl aminolaevulinate and hexyl aminolaevulinate cream.
Topics: Adolescent; Adult; Aminolevulinic Acid; Double-Blind Method; Erythema; Female; Humans; Hyperpigmenta | 2007 |
Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial.
Topics: Acne Vulgaris; Adult; Aminolevulinic Acid; Edema; Erythema; Female; Fluorescence; Humans; Laser Ther | 2008 |
18 other studies available for aminolevulinic acid and Erythema
| Article | Year |
|---|---|
Adverse reactions of ALA-PDT for the treatment of cutaneous diseases: A retrospective study.
Topics: Aged; Aminolevulinic Acid; China; Erythema; Female; Humans; Hyperpigmentation; Hypopigmentation; Pho | 2022 |
Photodynamic therapy for actinic keratosis in vegan and omnivore patients: the role of diet on skin healing.
Topics: Aged; Aminolevulinic Acid; Diet; Erythema; Female; Humans; Keratosis, Actinic; Male; Middle Aged; Ph | 2021 |
The acute inflammatory response to photodynamic therapy.
Topics: Aminolevulinic Acid; Dinoprostone; Erythema; Female; Humans; Male; Nitric Oxide; Photosensitizing Ag | 2013 |
Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema.
Topics: Adult; Aminolevulinic Acid; Erythema; Female; Humans; Male; Photochemotherapy; Photosensitizing Agen | 2014 |
Temperature-modulated photodynamic therapy for the treatment of actinic keratosis on the extremities: a pilot study.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Blister; Clinical Protocols; Erythema; Extremities; Fe | 2014 |
Correlation between treatment time, photobleaching, inflammation and pain after photodynamic therapy with methyl aminolevulinate on tape-stripped skin in healthy volunteers.
Topics: Adult; Aminolevulinic Acid; Erythema; Fluorescence; Forearm; Humans; Inflammation; Male; Middle Aged | 2015 |
Topical aminolaevulinic acid- and aminolaevulinic acid methyl ester-based photodynamic therapy with red and violet light: influence of wavelength on pain and erythema.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Animals; Erythema; Humans; Lasers; Mice; Mice, | 2009 |
Photosensitization induced by exposure to colour cathode ray tube monitor following topical 5-aminolaevulinic acid-based photodynamic therapy: a case report.
Topics: Acne Vulgaris; Administration, Topical; Adult; Aminolevulinic Acid; Cathode Ray Tube; Computer Termi | 2010 |
Increased cutaneous oxygen availability by topical application of hydrogen peroxide cream enhances the photodynamic reaction to topical 5-aminolevulinic acid-methyl ester.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Erythema; Female; Huma | 2011 |
Oil components modulate the skin delivery of 5-aminolevulinic acid and its ester prodrug from oil-in-water and water-in-oil nanoemulsions.
Topics: Administration, Topical; Aminolevulinic Acid; Analysis of Variance; Animals; Drug Delivery Systems; | 2011 |
The characteristics of erythema induced by topical 5-aminolaevulinic acid photodynamic therapy.
Topics: Aminolevulinic Acid; Erythema; Humans; Microscopy, Fluorescence; Photochemotherapy; Photosensitizing | 2004 |
Photodynamic therapy for the treatment of erythema, papules, pustules, and severe flushing consistent with rosacea.
Topics: Aminolevulinic Acid; Erythema; Female; Flushing; Humans; Middle Aged; Photochemotherapy; Photosensit | 2006 |
Late erythema after photodynamic therapy to the face.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Carcinoma, Basal Cell; Cheek; Erythema; Humans; | 2006 |
Histamine is released following aminolevulinic acid-photodynamic therapy of human skin and mediates an aminolevulinic acid dose-related immediate inflammatory response.
Topics: Adult; Aged; Aminolevulinic Acid; Cetirizine; Dose-Response Relationship, Drug; Erythema; Female; Hi | 2006 |
Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin.
Topics: Adult; Aminolevulinic Acid; Dose-Response Relationship, Radiation; Erythema; Female; Fluorescent Dye | 1997 |
Photodynamic treatment of skin malignancies with aminolevulinic acid. Emphasis on anatomical observations and in vivo erythema visual assessment.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Basal Cell; Erythema; Female; Follow-Up Studi | 1996 |
Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Erythema; Female; Fluorescenc | 1997 |
A quantitative assessment of protoporphyrin IX metabolism and phototoxicity in human skin following dose-controlled delivery of the prodrugs 5-aminolaevulinic acid and 5-aminolaevulinic acid-n-pentylester.
Topics: Adult; Aminolevulinic Acid; Dose-Response Relationship, Drug; Erythema; Female; Humans; Iontophoresi | 2001 |